The ADDF accelerates the discovery of drugs to prevent and treat Alzheimer's disease through research funding and portfolio management.
The Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to advancing the discovery of drugs to prevent and treat Alzheimer's disease. ADDF funds research programs focused on drug development, biomarkers, and prevention strategies. In 2024, ADDF catalyzed significant breakthroughs, including major investments in scalable blood tests and the cataloging of Alzheimer's biomarkers. The foundation also marked the 10th anniversary of the Goodes Prize and celebrated the FDA approval of Kisunla (Donanemab). ADDF's diverse portfolio is one of the largest worldwide, emphasizing lifestyle interventions and innovative diagnostics.
Flinders University's College of Education, Psychology and Social Work equips students with skills, commitment, and vision to protect vulnerable communities and advance human development through world-class teaching and research.
The Cognitive Neuroscience Center is a key experimental platform at Fudan University, focusing on understanding the neural mechanisms of human cognitive activities and their role in advanced cognitive functions.
X-MOL Academic Platform provides a platform for academic research and collaboration, with a focus on chemistry and materials science.